By 2025 the global therapeutic peptide market is expected to reach sales of >$49 billion. As the market grows and the use of therapeutic peptides increases there remains significant challenges with peptide delivery such as:
- Poor solubility
- Gel formation
- Formation of fibrils or particles
- Hydrolytic cleavage
- Formation of charge variants
- The Arestat™ technology overcomes these challenges and enables superior format of therapeutic peptide products
What Arecor can do
Arecor has an excellent track record developing difficult-to-achieve product profiles where our competitors cannot. Our Arestat™ technology offers a series of formulation options that have been specifically designed to overcome challenges associated with delivering stable aqueous formulations of therapeutic peptides.
Arecor is leveraging its unique formulation platform to develop a portfolio of proprietary products enabling improved treatments for diabetes – see our products.